Clinical Trial Search

Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005

Primary: Passing the Week 117 DBPCFC to Peanut — 21; 19; 1 participants

Primary: Determine the Percentage of Patients Tolerating the 12-month DBPCFC — 2; 10 Participants

Primary: Consistency of High Threshold Reactivity — 6 Participants

Primary: Number of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without…

Primary: Desensitisation to >1.4g (Roasted) Peanut Protein at Food Challenge — 24; 14 Participants — p=<0.0001

Primary: Tolerance or Sustained Unresponsiveness — 2; 7 Participants

Primary: The Percentage of Subjects Who Pass the 20gm Peanut Flour (~50% Peanut Protein) Oral Food Challenge 2-4 Weeks After Discontinuing Peanut OIT Therapy — 3; 1 Participants

Primary: Population Sensitization Threshold in mg Peanut Protein Predicted to Provoke Reactions in 5% of the Peanut-allergic Population — 160; 300 mg

Primary: Percent of Participants Who Successfully Consumed 5,000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral…

Primary: Percentage of Children That Tolerate the Full Challenge — 100; 21 percentage of participants

Primary: The Amount of Peanut Protein Ingested Before An Allergic Reaction is Observed During the Double-blind, Placebo Controlled Food Challenge (DBPCFC) After Completing…

Primary: The Percentage of Subjects Who Tolerate at Least 300 mg (443 mg Cumulative) of Peanut Protein With no More Than Mild Symptoms at the Exit DBPCFC — 23; 5 Participants…

Primary: Percentage of Participants Desensitized to Peanut Protein After 134 Weeks of Oral Immunotherapy (OIT) — 71; 2 Percentage of Participants — p=<0.0001

Primary: Percentage of Treatment Responders at Month 12; Analyzed in Overall Population — 45.3; 41.1; 50.0; 25.0 percentage of participants — p=0.0292

Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants

Primary: Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg) — 13 participants

Primary: Desensitization After 36 Months of Peanut SLIT or Placebo SLIT — 4.9; 2.5 score on a scale — p=0.002

Primary: Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24 — 8.3 Percentage of Participants

Primary: Determine the Percentage of Subjects Who Demonstrate Sustained Unresponsiveness (SU) by a Negative Double-blind Placebo-controlled Food Challenge (DBPCFC). — 29…

Primary: Number of Participants With Treatment-related Adverse Events (AEs) — 7 Participants

Primary: Number of Participants With Induced Peanut Desensitization at 12 Months — 9; 7 Participants

Primary: Anaphylaxis Occurrence Rates in Each Group — 9; 10 Participants — p=0.77

Primary: Desensitisation — 7; 5; 2 Participants

Primary: Percentage of Subjects Who Can Tolerate the Peanut Oral Food Challenge After 12 Months of Peanut SLIT Dosing — 45.5; 0; 11.8; 66.7 percentage of participants

Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants

Primary: The Level of Allergen Consumed Post-oral Immunotherapy — 6; 300 milligrams

Primary: Number of Participants With Peanut Allergy at 60 Months of Age - by Skin Prick Test Stratum — 36; 5; 18; 5 Participants — p=<0.0001

Primary: Percentage of Subjects Achieving Tolerance as Defined by a Negative DBPCFC 4 Weeks After Discontinuation of Peanut OIT Therapy. — 89 percentage of participants

Primary: Percentage of Participants Experiencing Treatment-emergent Adverse Events During the 2-stage Study Sequence (Safety) — 60 percentage of participants